Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rBPI21 in burn injury
NCT00462904Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2006
- Primary completion
- Nov 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of opebacan in burn injury, sponsored by UT Southwestern Medical Center. Primary endpoint: Plasma Levels of Bactericidal/Permeability-increasing Protein. Started Apr 2006; status: terminated.
02
Drugs
opebacan
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT00462904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00462904.